A carregar...
Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery
PURPOSE: KPI-121 is a nanoparticle suspension of loteprednol etabonate with improved ocular pharmacokinetics compared with marketed formulations. The efficacy and safety of KPI-121 1% ophthalmic suspension (INVELTYS™) dosed twice daily (BID) were evaluated in participants who had undergone cataract...
Na minha lista:
| Publicado no: | Clin Ophthalmol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6311334/ https://ncbi.nlm.nih.gov/pubmed/30643381 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S185800 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|